Two leading medical stocks that appear reasonable at current levels are AbbVie (NYSE: ABBV) and Merck (NYSE: MRK). The former ...

As Big Pharma braces for a massive revenue crash when patents on blockbuster drugs expire, an unexpected player is stepping ...

The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its ...

Formycon will develop, register, manufacture, and supply the product, while Zydus will be responsible for commercialization.

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

FDA reexamine infant RSV therapies with Sanofi, AstraZeneca, and Merck amid safety concerns and data review under new FDA leadership.

The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly ...

In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...

MARTINSRIED, Germany, Dec. 9, 2025 /CNW/ — Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences ...

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for ...